TABLE 2.
Association of combined stromal LOX‐1 and CD8 status with clinicopathological factors in 128 CRC patients
| Stromal LOX‐1/CD8+ CTL status | |||||
|---|---|---|---|---|---|
| H/H | H/L | L/H | L/L | ||
| Factors | n = 30 (%) | n = 32 (%) | n = 31 (%) | n = 35 (%) | P value |
| Sex | |||||
| Female | 12 (40.0) | 11 (34.4) | 12 (38.7) | 13 (37.1) | .972 |
| Male | 18 (60.0) | 21 (65.6) | 19 (61.3) | 22 (62.9) | |
| Age | |||||
| ≤70 | 20 (66.7) | 24 (75.0) | 22 (71.0) | 20 (57.1) | .442 |
| >70 | 10 (33.3) | 8 (25.0) | 9 (29.0) | 15 (42.9) | |
| T stage | |||||
| T0, T1 | 4 (13.3) | 1 (3.1) | 2 (6.5) | 6 (17.1) | .178 |
| T2 | 6 (20.0) | 4 (12.5) | 2 (6.5) | 2 (5.7) | |
| T3 | 18 (60.0) | 20 (62.5) | 19 (61.3) | 17 (48.6) | |
| T4 | 2 (6.7) | 7 (21.9) | 8 (25.8) | 10 (28.6) | |
| N stage | |||||
| N0 | 18 (60.0) | 11 (34.3) | 18 (58.1) | 15 (42.9) | .06 |
| N1 | 10 (33.3) | 18 (56.3) | 7 (22.6) | 12 (34.3) | |
| N2 | 2 (6.7) | 3 (9.4) | 6 (19.4) | 8 (22.9) | |
| M stage | |||||
| M0 | 26 (86.7) | 23 (71.9) | 24 (77.4) | 26 (74.3) | .528 |
| M1 | 4 (13.3) | 9 (28.1) | 7 (22.6) | 9 (25.7) | |
| TNM stage | |||||
| 0 | 0 (0) | 0 (0) | 2 (6.5) | 1 (2.9) | .084 |
| I | 7 (23.3) | 1 (3.2) | 2 (6.5) | 5 (14.3) | |
| II | 9 (30.0) | 8 (25.0) | 13 (41.9) | 5 (14.3) | |
| III | 10 (33.3) | 14 (43.8) | 7 (22.6) | 15 (42.9) | |
| IV | 4 (13.3) | 9 (28.1) | 7 (22.6) | 9 (25.7) | |
| Lymphatic invasion | |||||
| Negative | 6 (20.0) | 5 (15.6) | 4 (12.9) | 6 (17.1) | .899 |
| Positive | 24 (80.0) | 27 (84.4) | 27 (87.1) | 29 (82.9) | |
| Venous invasion | |||||
| Negative | 13 (43.3) | 8 (25.0) | 13 (41.9) | 16 (45.7) | .302 |
| Positive | 17 (56.7) | 24 (75.0) | 18 (58.1) | 19 (54.3) | |
| Histological differentiation | |||||
| Well | 9 (30.0) | 9 (28.1) | 8 (25.8) | 10 (28.6) | .922 |
| Moderately | 19 (63.3) | 22 (68.8) | 20 (64.5) | 21 (60.0) | |
| Others | 2 (6.7) | 1 (3.1) | 3 (9.7) | 4 (11.4) | |
| KRAS variant | |||||
| Wild | 17 (68.0) | 10 (47.6) | 14 (63.6) | 13 (65.0) | .527 |
| Mutation | 8 (32.0) | 11 (52.4) | 8 (36.4) | 7 (35.0) | |
| BRAF variant | |||||
| Wild | 24 (96.0) | 21 (100) | 21 (95.5) | 19 (95.0) | .895 |
| Mutation | 1 (4.0) | 0 (0) | 1 (4.5) | 1 (5.0) | |
Abbreviations: stromal LOX‐1‐L, ≤534.4/mm2; stromal LOX‐1 score‐H, > 534.4/mm2; CD8+ CTL‐L, ≤103.4/mm2; CD8+ CTL‐H, >103.4/mm2.
*
P < .05 is considered significant. P‐values were calculated using Chi‐square tests.